MannKind to Present at Upcoming Investor Conferences
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD), a developer of inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in four upcoming investor conferences in September 2025.
CEO Michael Castagna and CFO Chris Prentiss will present at the Wells Fargo Health Care Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 9), and Morgan Stanley Global Healthcare Conference (Sept. 9). Live webcasts will be available on MannKind's investor relations website, with recordings accessible for 90 days post-event.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
In the Aug 28 session, MNKD declined 0.66%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.4% during that session. Our momentum scanner triggered 48 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind’s Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:
Wells Fargo Health Care Conference (Boston)
Wednesday, September 3, 4:30 p.m. ET
Cantor Global Healthcare Conference (New York)
Thursday, September 4, 9:45 a.m. ET
H.C. Wainwright 27th Annual Global Investment Conference (New York)
Tuesday, September 9, 11:30 a.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference (New York)
Tuesday, September 9, 2:35 p.m. ET
Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind: Investor Relations Ana Kapor (818) 661-5000 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com